Siplizumab
Siplizumab is an antibody pharmaceutical. It is currently being investigated in clinical studies. It is known to target T-cell surface antigen CD2.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
15 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Psoriasis | D011565 | EFO_0000676 | L40 | — | 2 | — | — | 1 | 3 |
| Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | 1 | 2 | — | — | — | 2 |
| Leukemia | D007938 | C95 | 1 | 1 | — | — | — | 2 | |
| Lymphoma | D008223 | C85.9 | 1 | 1 | — | — | — | 2 | |
| Kidney transplantation | D016030 | — | 1 | — | — | — | 1 | ||
| Myelodysplastic syndromes | D009190 | D46 | — | 1 | — | — | — | 1 | |
| Multiple myeloma | D009101 | C90.0 | — | 1 | — | — | — | 1 | |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | 1 | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Graft vs host disease | D006086 | D89.81 | 3 | — | — | — | — | 3 | |
| Neoplasms | D009369 | C80 | 2 | — | — | — | — | 2 | |
| Renal insufficiency | D051437 | HP_0000083 | N19 | 1 | — | — | — | — | 1 |
| T-cell lymphoma | D016399 | 1 | — | — | — | — | 1 | ||
| T-cell lymphoma peripheral | D016411 | C84.9 | 1 | — | — | — | — | 1 | |
| Kidney diseases | D007674 | EFO_0003086 | N08 | 1 | — | — | — | — | 1 |
| Lymphoproliferative disorders | D008232 | Orphanet_2442 | D47.9 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | SIPLIZUMAB |
| INN | siplizumab |
| Description | Siplizumab (humanized mab) |
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 288392-69-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2108742 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB06371 |
| UNII ID | KUW1QG1ZM3 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
CD2
CD2
Organism
Homo sapiens
Gene name
CD2
Gene synonyms
SRBC
NCBI Gene ID
Protein name
T-cell surface antigen CD2
Protein synonyms
CD2, CD2 antigen (p50), sheep red blood cell receptor, Erythrocyte receptor, LFA-2, LFA-3 receptor, lymphocyte-function antigen-2, Rosette receptor, T-cell surface antigen T11/Leu-5
Uniprot ID
Mouse ortholog
Cd2 (12481)
T-cell surface antigen CD2 (Q61394)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 89 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more